close
Skip to main content

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1003))

Abstract

Myocarditis is the inflammation of the muscle tissues of the heart (myocardium). After a pathologic cardiac-specific inflammatory process, it may progress to chronic damage and dilated cardiomyopathy. The latter is characterized by systolic dysfunction, whose clinical correlate is heart failure. Nevertheless, other acute complications may arise as consequence of tissue damage and electrophysiologic disturbances. Different etiologies are involved in triggering myocarditis. In some cases, such as giant cell myocarditis or eosinophilic necrotizing myocarditis, it is an autoimmune process. Several factors predispose the development of autoimmune myocarditis such as systemic/local primary autoimmunity, viral infection, HLA and gender bias, exposure of cryptic antigens, mimicry, and deficient thymic training/Treg induction. Once the anti-myocardium autoimmune process is triggered, several components of the immune response orchestrate a sustained attack toward myocardial tissues with particular timing and immunopathogenic features. Innate response mediated by monocytes/macrophages, neutrophils, and eosinophils parallels the adaptive response, playing a final effector role and not only a priming function. Stromal cells like fibroblast are also involved in the process through specific cytokines. Furthermore, adaptive T cell responses have anti-paradigmatic features, as Th17 response is dispensable for acute myocarditis but is the main driver of the process leading to dilated cardiomyopathy. Humoral response, thought to be a bystander, is important in the appearance of late-stage hemodynamic complications. The complexity of that process, as well as the unspecific and variable clinical presentation, had generated difficulties for diagnosis and treatment, which remain suboptimal. In this chapter, we will discuss the most relevant immunopathogenic findings from a basic science and clinical perspective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+
from $39.99 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - view details
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - view details

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun. 2008;30(1–2):5–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bracamonte-Baran W, Burlingham W. Non-inherited maternal antigens, pregnancy, and allotolerance. Biom J. 2015;38(1):39–51.

    Google Scholar 

  3. Ozen S, Bilginer Y. A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol. 2014;10(3):135–47.

    Article  CAS  PubMed  Google Scholar 

  4. Caforio AL, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636–48, 2648a–2648d.

    Google Scholar 

  5. Kindermann I, et al. Update on myocarditis. J Am Coll Cardiol. 2012;59(9):779–92.

    Article  PubMed  Google Scholar 

  6. Pollack A, et al. Viral myocarditis-diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015;12(11):670–80.

    Article  PubMed  Google Scholar 

  7. Fabre A, Sheppard MN. Sudden adult death syndrome and other non-ischaemic causes of sudden cardiac death. Heart. 2006;92(3):316–20.

    Article  CAS  PubMed  Google Scholar 

  8. Cihakova D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol. 2008;99:95–114.

    Article  CAS  PubMed  Google Scholar 

  9. Ekstrom K, et al. Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail. 2016;18(12):1452–8.

    Article  PubMed  CAS  Google Scholar 

  10. Cooper LT, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol. 2007;50(19):1914–31.

    Article  PubMed  Google Scholar 

  11. Kindermann I, et al. Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118(6):639–48.

    Article  PubMed  Google Scholar 

  12. Daubeney PE, et al. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation. 2006;114(24):2671–8.

    Article  PubMed  Google Scholar 

  13. Doolan A, Langlois N, Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust. 2004;180(3):110–2.

    PubMed  Google Scholar 

  14. Baccouche H, et al. Diagnostic synergy of non-invasive cardiovascular magnetic resonance and invasive endomyocardial biopsy in troponin-positive patients without coronary artery disease. Eur Heart J. 2009;30(23):2869–79.

    Article  CAS  PubMed  Google Scholar 

  15. Abdel-Aty H, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815–22.

    Article  PubMed  Google Scholar 

  16. Aletras AH, et al. ACUT2E TSE-SSFP: a hybrid method for T2-weighted imaging of edema in the heart. Magn Reson Med. 2008;59(2):229–35.

    Article  PubMed  Google Scholar 

  17. Basso C, et al. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings. Cardiovasc Res. 2001;50(2):290–300.

    Article  CAS  PubMed  Google Scholar 

  18. Gore I, Saphir O. Myocarditis; a classification of 1402 cases. Am Heart J. 1947;34(6):827–30.

    Article  CAS  PubMed  Google Scholar 

  19. Richardson P, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93(5):841–2.

    Article  CAS  PubMed  Google Scholar 

  20. Felker GM, et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore). 1999;78(4):270–83.

    Article  CAS  Google Scholar 

  21. Towbin JA, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867–76.

    Article  CAS  PubMed  Google Scholar 

  22. Cooper LT. Molecular biologic detection of virus infection in myocarditis and dilated cardiomyopathy. In: Cooper LT, editor. Myocarditis: from bench to bedside. Totowa: Humana Press; 2002. P. 295–324.

    Google Scholar 

  23. Leone O, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol. 2012;21(4):245–74.

    Article  PubMed  Google Scholar 

  24. Yilmaz A, et al. Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis. Heart. 2008;94(11):1456–63.

    Article  CAS  PubMed  Google Scholar 

  25. Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113(4):593–5.

    Article  PubMed  Google Scholar 

  26. Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol. 1987;18(6):619–24.

    Article  CAS  PubMed  Google Scholar 

  27. Okura Y, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003;41(2):322–9.

    Article  PubMed  Google Scholar 

  28. Cooper LT Jr, et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol. 2008;102(11):1535–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Maleszewski JJ, et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol. 2015;115(12):1733–8.

    Article  PubMed  Google Scholar 

  30. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis – natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med. 1997;336(26):1860–6.

    Article  PubMed  Google Scholar 

  31. Cooper LT Jr, et al. Giant cell myocarditis. J Heart Lung Transplant. 1995;14(2):394–401.

    PubMed  Google Scholar 

  32. Kong G, et al. Response of recurrent giant cell myocarditis in a transplanted heart to intensive immunosuppression. Eur Heart J. 1991;12(4):554–7.

    Article  CAS  PubMed  Google Scholar 

  33. Gries W, et al. Giant cell myocarditis: first report of disease recurrence in the transplanted heart. J Heart Lung Transplant. 1992;11(2 Pt 1):370–4.

    CAS  PubMed  Google Scholar 

  34. Grant SC. Giant cell myocarditis in a transplanted heart. Eur Heart J. 1993;14(10):1437.

    Article  CAS  PubMed  Google Scholar 

  35. Grant SC. Recurrent giant cell myocarditis after transplantation. J Heart Lung Transplant. 1993;12(1 Pt 1):155–6.

    CAS  PubMed  Google Scholar 

  36. Barin JG, et al. Fatal eosinophilic myocarditis develops in the absence of IFN-gamma and IL-17A. J Immunol. 2013;191(8):4038–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Busteed S, et al. Myocarditis as a prognostic indicator in systemic lupus erythematosus. Postgrad Med J. 2004;80(944):366–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Levin MD, Zoet-Nugteren SK, Markusse HM. Myocarditis and primary Sjogren’s syndrome. Lancet. 1999;354(9173):128–9.

    Article  CAS  PubMed  Google Scholar 

  39. Barbaro G. Cardiovascular manifestations of HIV infection. Circulation. 2002;106(11):1420–5.

    Article  PubMed  Google Scholar 

  40. Frustaci A, et al. Biopsy-proven autoimmune myocarditis in HIV-associated dilated cardiomyopathy. BMC Infect Dis. 2014;14:729.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Halsell JS, et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA. 2003;289(24):3283–9.

    Article  PubMed  Google Scholar 

  42. Root-Bernstein R, Fairweather D. Unresolved issues in theories of autoimmune disease using myocarditis as a framework. J Theor Biol. 2015;375:101–23.

    Article  PubMed  Google Scholar 

  43. Fairweather D, Rose NR. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods. 2007;41(1):118–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cihakova D, et al. Animal models for autoimmune myocarditis and autoimmune thyroiditis. Methods Mol Med. 2004;102:175–93.

    CAS  PubMed  Google Scholar 

  45. Donermeyer DL, et al. Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. J Exp Med. 1995;182(5):1291–300.

    Article  CAS  PubMed  Google Scholar 

  46. Pummerer CL, et al. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J Clin Invest. 1996;97(9):2057–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Li HS, Ligons DL, Rose NR. Genetic complexity of autoimmune myocarditis. Autoimmun Rev. 2008;7(3):168–73.

    Article  CAS  PubMed  Google Scholar 

  48. Barin JG, Cihakova D. Control of inflammatory heart disease by CD4+ T cells. Ann N Y Acad Sci. 2013;1285:80–96.

    Article  CAS  PubMed  Google Scholar 

  49. Frisancho-Kiss S, et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178(11):6710–4.

    Article  CAS  PubMed  Google Scholar 

  50. Goser S, et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation. 2006;114(16):1693–702.

    Article  PubMed  CAS  Google Scholar 

  51. Elliott JF, et al. Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD mice. Proc Natl Acad Sci U S A. 2003;100(23):13447–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Tarrio ML, et al. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188(10):4876–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Wang J, et al. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22(6):443–52.

    Article  CAS  PubMed  Google Scholar 

  54. Keir ME, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.

    Article  CAS  PubMed  Google Scholar 

  55. Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111(12):2214–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Page DB, et al. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65:185–202.

    Article  CAS  PubMed  Google Scholar 

  57. Laubli H, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015;3:11.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Henke A, et al. The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol. 1995;69(11):6720–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Huber SA, Gauntt CJ, Sakkinen P. Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction, and immunopathogenicity. Adv Virus Res. 1998;51:35–80.

    Article  CAS  PubMed  Google Scholar 

  60. Fuse K, et al. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation. 2005;112(15):2276–85.

    Article  CAS  PubMed  Google Scholar 

  61. Fairweather D, Frisancho-Kiss S, Rose NR. Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis. Rev Med Virol. 2005;15(1):17–27.

    Article  CAS  PubMed  Google Scholar 

  62. Wolfgram LJ, et al. Variations in the susceptibility to Coxsackievirus B3-induced myocarditis among different strains of mice. J Immunol. 1986;136(5):1846–52.

    CAS  PubMed  Google Scholar 

  63. Fairweather D, et al. IL-12 protects against coxsackievirus B3-induced myocarditis by increasing IFN-gamma and macrophage and neutrophil populations in the heart. J Immunol. 2005;174(1):261–9.

    Article  CAS  PubMed  Google Scholar 

  64. Feldman AM, McNamara D. Myocarditis. N Engl J Med. 2000;343(19):1388–98.

    Article  CAS  PubMed  Google Scholar 

  65. Mahfoud F, et al. Blood pressure and heart rate predict outcome in patients acutely admitted with suspected myocarditis without previous heart failure. J Hypertens. 2012;30(6):1217–24.

    Article  CAS  PubMed  Google Scholar 

  66. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Parks CG, et al. Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int J Mol Sci. 2014;15(8):14269–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Ansari A, Maron BJ, Berntson DG. Drug-induced toxic myocarditis. Tex Heart Inst J. 2003;30(1):76–9.

    PubMed  PubMed Central  Google Scholar 

  69. Feenstra J, et al. Drug-induced heart failure. J Am Coll Cardiol. 1999;33(5):1152–62.

    Article  CAS  PubMed  Google Scholar 

  70. Lo MH, et al. Drug reaction with eosinophilia and systemic symptoms syndrome associated myocarditis: a survival experience after extracorporeal membrane oxygenation support. J Clin Pharm Ther. 2013;38(2):172–4.

    Article  CAS  PubMed  Google Scholar 

  71. Madan R, et al. Radiation induced heart disease: pathogenesis, management and review literature. J Egypt Natl Canc Inst. 2015;27(4):187–93.

    Article  CAS  PubMed  Google Scholar 

  72. Rose NR. Viral myocarditis. Curr Opin Rheumatol. 2016;28(4):383–9.

    Article  CAS  PubMed  Google Scholar 

  73. Wessely R, et al. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest. 1998;102(7):1444–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Wessely R, et al. Low-level expression of a mutant coxsackieviral cDNA induces a myocytopathic effect in culture: an approach to the study of enteroviral persistence in cardiac myocytes. Circulation. 1998;98(5):450–7.

    Article  CAS  PubMed  Google Scholar 

  75. Badorff C, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5(3):320–6.

    Article  CAS  PubMed  Google Scholar 

  76. Kearney MT, et al. Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J. 2001;77(903):4–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Lodge PA, et al. Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. Am J Pathol. 1987;128(3):455–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Ong S, et al. Natural killer cells limit cardiac inflammation and fibrosis by halting eosinophil infiltration. Am J Pathol. 2015;185(3):847–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Yao HL, et al. Gene expression analysis during recovery process indicates the mechanism for innate immune injury and repair from Coxsackievirus B3-induced myocarditis. Virus Res. 2016;213:314–21.

    Article  CAS  PubMed  Google Scholar 

  80. Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Rev Endocr Metab Disord. 2016;17(4):485–98.

    Article  CAS  PubMed  Google Scholar 

  81. Fairweather D, et al. From infection to autoimmunity. J Autoimmun. 2001;16(3):175–86.

    Article  CAS  PubMed  Google Scholar 

  82. Phongsisay V. The immunobiology of Campylobacter jejuni: innate immunity and autoimmune diseases. Immunobiology. 2016;221(4):535–43.

    Article  CAS  PubMed  Google Scholar 

  83. Caforio AL, Mahon NJ, McKenna WJ. Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy. Autoimmunity. 2001;34(3):199–204.

    Article  CAS  PubMed  Google Scholar 

  84. Massilamany C, et al. Identification of novel mimicry epitopes for cardiac myosin heavy chain-alpha that induce autoimmune myocarditis in A/J mice. Cell Immunol. 2011;271(2):438–49.

    Article  CAS  PubMed  Google Scholar 

  85. Tzolovsky G, et al. Identification and phylogenetic analysis of Drosophila melanogaster myosins. Mol Biol Evol. 2002;19(7):1041–52.

    Article  CAS  PubMed  Google Scholar 

  86. Li Y, et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006;177(11):8234–40.

    Article  CAS  PubMed  Google Scholar 

  87. Moudgil KD, Sercarz EE. Crypticity of self antigenic determinants is the cornerstone of a theory of autoimmunity. Discov Med. 2005;5(28):378–82.

    PubMed  Google Scholar 

  88. Park AC, et al. Mucosal administration of collagen V ameliorates the atherosclerotic plaque burden by inducing interleukin 35-dependent tolerance. J Biol Chem. 2016;291(7):3359–70.

    Article  CAS  PubMed  Google Scholar 

  89. Lv H, et al. Impaired thymic tolerance to alpha-myosin directs autoimmunity to the heart in mice and humans. J Clin Invest. 2011;121(4):1561–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Carlquist JF, et al. HLA class II (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Validation study and meta-analysis of published HLA association studies. Circulation. 1991;83(2):515–22.

    Article  CAS  PubMed  Google Scholar 

  91. Limas CJ, Limas C. HLA antigens in idiopathic dilated cardiomyopathy. Br Heart J. 1989;62(5):379–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Martinetti M, et al. HLA and immunoglobulin polymorphisms in idiopathic dilated cardiomyopathy. Hum Immunol. 1992;35(3):193–9.

    Article  CAS  PubMed  Google Scholar 

  93. Liu W, et al. Association of HLA class II DRB1, DPA1 and DPB1 polymorphism with genetic susceptibility to idiopathic dilated cardiomyopathy in Chinese Han nationality. Autoimmunity. 2006;39(6):461–7.

    Article  CAS  PubMed  Google Scholar 

  94. Rodriguez-Perez JM, et al. MHC class II genes in Mexican patients with idiopathic dilated cardiomyopathy. Exp Mol Pathol. 2007;82(1):49–52.

    Article  CAS  PubMed  Google Scholar 

  95. Lozano MD, et al. Human leukocyte antigen class II associations in patients with idiopathic dilated cardiomyopathy. Myocarditis Treatment Trial Investigators. J Card Fail. 1997;3(2):97–103.

    Article  CAS  PubMed  Google Scholar 

  96. Neu N, et al. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. 1987;139(11):3630–6.

    CAS  PubMed  Google Scholar 

  97. Taneja V, et al. Spontaneous myocarditis mimicking human disease occurs in the presence of an appropriate MHC and non-MHC background in transgenic mice. J Mol Cell Cardiol. 2007;42(6):1054–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Guler ML, et al. Two autoimmune diabetes loci influencing T cell apoptosis control susceptibility to experimental autoimmune myocarditis. J Immunol. 2005;174(4):2167–73.

    Article  CAS  PubMed  Google Scholar 

  99. Aly M, et al. Complex genetic control of host susceptibility to coxsackievirus B3-induced myocarditis. Genes Immun. 2007;8(3):193–204.

    Article  CAS  PubMed  Google Scholar 

  100. Lin A, et al. 14 bp deletion polymorphism in the HLA-G gene is a risk factor for idiopathic dilated cardiomyopathy in a Chinese Han population. Tissue Antigens. 2007;70(5):427–31.

    Article  CAS  PubMed  Google Scholar 

  101. Hviid TV, Christiansen OB. Linkage disequilibrium between human leukocyte antigen (HLA) class II and HLA-G – possible implications for human reproduction and autoimmune disease. Hum Immunol. 2005;66(6):688–99.

    Article  CAS  PubMed  Google Scholar 

  102. Seko Y, et al. Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. Cardiovasc Res. 2007;75(1):158–67.

    Article  CAS  PubMed  Google Scholar 

  103. Futamatsu H, et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res. 2003;59(1):95–104.

    Article  CAS  PubMed  Google Scholar 

  104. Abramson J, Goldfarb Y. AIRE: From promiscuous molecular partnerships to promiscuous gene expression. Eur J Immunol. 2016;46(1):22–33.

    Article  CAS  PubMed  Google Scholar 

  105. Abramson J, Husebye ES. Autoimmune regulator and self-tolerance – molecular and clinical aspects. Immunol Rev. 2016;271(1):127–40.

    Article  CAS  PubMed  Google Scholar 

  106. Metzger TC, Anderson MS. Control of central and peripheral tolerance by Aire. Immunol Rev. 2011;241(1):89–103.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Malchow S, et al. Aire enforces immune tolerance by directing autoreactive T cells into the regulatory T cell lineage. Immunity. 2016;44(5):1102–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Metzger TC, Anderson MS. Myocarditis: a defect in central immune tolerance? J Clin Invest. 2011;121(4):1251–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 1991;147(7):2141–7.

    CAS  PubMed  Google Scholar 

  110. Takaba H, et al. Fezf2 orchestrates a thymic program of self-antigen expression for immune tolerance. Cell. 2015;163(4):975–87.

    Article  CAS  PubMed  Google Scholar 

  111. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci. 2010;1183:211–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol. 2013;25(4):305–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Afanasyeva M, et al. Interleukin-12 receptor/STAT4 signaling is required for the development of autoimmune myocarditis in mice by an interferon-gamma-independent pathway. Circulation. 2001;104(25):3145–51.

    Article  CAS  PubMed  Google Scholar 

  114. Pope RM, Shahrara S. Possible roles of IL-12-family cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(4):252–6.

    Article  CAS  PubMed  Google Scholar 

  115. Sonderegger I, et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol. 2006;36(11):2849–56.

    Article  CAS  PubMed  Google Scholar 

  116. Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol. 2013;4:315.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  117. Wu L, et al. Pathogenic IL-23 signaling is required to initiate GM-CSF-driven autoimmune myocarditis in mice. Eur J Immunol. 2016;46(3):582–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Eriksson U, et al. Dual role of the IL-12/IFN-gamma axis in the development of autoimmune myocarditis: induction by IL-12 and protection by IFN-gamma. J Immunol. 2001;167(9):5464–9.

    Article  CAS  PubMed  Google Scholar 

  119. Eriksson U, et al. Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation. 2001;103(1):18–21.

    Article  CAS  PubMed  Google Scholar 

  120. Rangachari M, et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med. 2006;203(8):2009–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Fairweather D, et al. Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol. 2004;165(6):1883–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Fairweather D, et al. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J Immunol. 2006;176(6):3516–24.

    Article  CAS  PubMed  Google Scholar 

  123. Cihakova D, et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol. 2008;172(5):1195–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Afanasyeva M, et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol. 2001;159(1):193–203.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Baldeviano GC, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res. 2010;106(10):1646–55.

    Article  CAS  PubMed  Google Scholar 

  126. Wu L, et al. Cardiac fibroblasts mediate IL-17A-driven inflammatory dilated cardiomyopathy. J Exp Med. 2014;211(7):1449–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Myers JM, et al. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight. 2016;1(9).

    Google Scholar 

  128. Chen P, et al. Susceptibility to autoimmune myocarditis is associated with intrinsic differences in CD4(+) T cells. Clin Exp Immunol. 2012;169(2):79–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. Shi Y, et al. Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway. Circulation. 2010;121(24):2624–34.

    Article  CAS  PubMed  Google Scholar 

  130. Brusko TM, Putnam AL, Bluestone JA. Human regulatory T cells: role in autoimmune disease and therapeutic opportunities. Immunol Rev. 2008;223:371–90.

    Article  CAS  PubMed  Google Scholar 

  131. Cheng HM, Chamley L. Cryptic natural autoantibodies and co-potentiators. Autoimmun Rev. 2008;7(6):431–4.

    Article  CAS  PubMed  Google Scholar 

  132. Caforio AL, et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002;4(4):411–7.

    Article  PubMed  Google Scholar 

  133. Wallukat G, Schimke I. Agonistic autoantibodies directed against G-protein-coupled receptors and their relationship to cardiovascular diseases. Semin Immunopathol. 2014;36(3):351–63.

    Article  CAS  PubMed  Google Scholar 

  134. Neumann DA, et al. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol. 1990;16(6):839–46.

    Article  CAS  PubMed  Google Scholar 

  135. Caforio AL, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation. 1992;85(5):1734–42.

    Article  CAS  PubMed  Google Scholar 

  136. Caforio AL, et al. Idiopathic dilated cardiomyopathy: lack of association between circulating organ-specific cardiac antibodies and HLA-DR antigens. Tissue Antigens. 1992;39(5):236–40.

    Article  CAS  PubMed  Google Scholar 

  137. Gu C, et al. Apoptotic signaling through the beta-adrenergic receptor. A new Gs effector pathway. J Biol Chem. 2000;275(27):20726–33.

    Article  CAS  PubMed  Google Scholar 

  138. Staudt Y, et al. Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol. 2003;466(1–2):1–6.

    Article  CAS  PubMed  Google Scholar 

  139. Christ T, et al. Autoantibodies against the beta1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol. 2001;33(8):1515–25.

    Article  CAS  PubMed  Google Scholar 

  140. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113(6):739–53.

    Article  CAS  PubMed  Google Scholar 

  141. Herda LR, et al. Effects of immunoadsorption and subsequent immunoglobulin G substitution on cardiopulmonary exercise capacity in patients with dilated cardiomyopathy. Am Heart J. 2010;159(5):809–16.

    Article  CAS  PubMed  Google Scholar 

  142. Trimpert C, et al. Immunoadsorption in dilated cardiomyopathy: long-term reduction of cardiodepressant antibodies. Eur J Clin Investig. 2010;40(8):685–91.

    Article  CAS  Google Scholar 

  143. Muller J, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101(4):385–91.

    Article  CAS  PubMed  Google Scholar 

  144. Haberland A, et al. Aptamer neutralization of beta1-adrenoceptor autoantibodies isolated from patients with cardiomyopathies. Circ Res. 2011;109(9):986–92.

    Article  CAS  PubMed  Google Scholar 

  145. Marquis JK, Grindel JM. Toxicological evaluation of oligonucleotide therapeutics. Curr Opin Mol Ther. 2000;2(3):258–63.

    CAS  PubMed  Google Scholar 

  146. Artis D, Spits H. The biology of innate lymphoid cells. Nature. 2015;517(7534):293–301.

    Article  CAS  PubMed  Google Scholar 

  147. Eberl G, Di Santo JP, Vivier E. The brave new world of innate lymphoid cells. Nat Immunol. 2015;16(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  148. Grabie N, et al. Neutrophils sustain pathogenic CD8+ T cell responses in the heart. Am J Pathol. 2003;163(6):2413–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. Barin JG, Rose NR, Cihakova D. Macrophage diversity in cardiac inflammation: a review. Immunobiology. 2012;217(5):468–75.

    Article  CAS  PubMed  Google Scholar 

  150. Bangert A, et al. Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci U S A. 2016;113(2):E155–64.

    Article  CAS  PubMed  Google Scholar 

  151. Su Z, et al. HMGB1 facilitated macrophage reprogramming towards a proinflammatory M1-like phenotype in experimental autoimmune myocarditis development. Sci Rep. 2016;6:21884.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Barin JG, et al. Macrophages participate in IL-17-mediated inflammation. Eur J Immunol. 2012;42(3):726–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  153. Jensen LD, Marchant DJ. Emerging pharmacologic targets and treatments for myocarditis. Pharmacol Ther. 2016;161:40–51.

    Article  CAS  PubMed  Google Scholar 

  154. Escher F, et al. Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy. Clin Res Cardiol. 2016;105(12):1011–20.

    Article  CAS  PubMed  Google Scholar 

  155. Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J. 2009;30(16):1995–2002.

    Article  CAS  PubMed  Google Scholar 

  156. Mason JW, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995;333(5):269–75.

    Article  CAS  PubMed  Google Scholar 

  157. Menghini VV, et al. Combined immunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clin Proc. 1999;74(12):1221–6.

    Article  CAS  PubMed  Google Scholar 

  158. Felix SB, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol. 2000;35(6):1590–8.

    Article  CAS  PubMed  Google Scholar 

  159. Knebel F, et al. Reduction of morbidity by immunoadsorption therapy in patients with dilated cardiomyopathy. Int J Cardiol. 2004;97(3):517–20.

    Article  PubMed  Google Scholar 

  160. Staudt A, et al. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Ther Apher Dial. 2006;10(1):42–8.

    Article  CAS  PubMed  Google Scholar 

  161. Kishimoto C, et al. Therapy with immunoglobulin in patients with acute myocarditis and cardiomyopathy: analysis of leukocyte balance. Heart Vessel. 2014;29(3):336–42.

    Article  Google Scholar 

  162. McNamara DM, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103(18):2254–9.

    Article  CAS  PubMed  Google Scholar 

  163. Kuhl U, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107(22):2793–8.

    Article  PubMed  CAS  Google Scholar 

  164. Zimmermann O, et al. Interferon beta-1b therapy in chronic viral dilated cardiomyopathy – is there a role for specific therapy? J Card Fail. 2010;16(4):348–56.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Daniela Čiháková.

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Bracamonte-Baran, W., Čiháková, D. (2017). Cardiac Autoimmunity: Myocarditis. In: Sattler, S., Kennedy-Lydon, T. (eds) The Immunology of Cardiovascular Homeostasis and Pathology. Advances in Experimental Medicine and Biology, vol 1003. Springer, Cham. https://doi.org/10.1007/978-3-319-57613-8_10

Download citation

Keywords

Publish with us

Policies and ethics